Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study

Florentino, Pilar T. V; Millington, Tristan; Silva, Thiago Cerqueira; Robertson, Chris; Oliveira, Vinicius de Araújo; Júnior, Juracy B S; Alves, Flávia J O; Penna, Gerson O; Katikireddi, Srinivasa Vital; Boaventura, Viviane S; Werneck, Guilherme L; Pearce, Neil; McCowan, Colin; Sullivan, Christopher; Agrawal, Utkarsh; Grange, Zoe; Ritchie, Lewis D; Simpson, Colin R; Sheikh, Aziz; Barreto, Mauricio L; Rudan, Igor; Barral Netto, Manoel; Paixão, Enny S.
Artículo en Inglés | ARCA | ID: arc-55114

Documentos relacionados

  1. Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case-control study.
  2. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil.
  3. Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study.
  4. BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: A prospective test-negative design study.
  5. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study.
  6. Effectiveness of BNT162b2 vaccine against symptomatic SARS-CoV-2 infection in children aged 5-11 years in Japan during Omicron variant predominate periods.
  7. Uptake, effectiveness and safety of COVID-19 vaccines in children and young people in Scotland: Protocol for early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II).
  8. CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study.
  9. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines.
  10. Investigating the uptake, effectiveness and safety of COVID-19 vaccines: protocol for an observational study using linked UK national data.